Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions.

 

Innovative chemistry enables efficient conjugation, optimised linkers, and payload selection, while addressing critical challenges such as linker bottlenecks, photosensitiser compatibility, and product homogeneity. A Photo-ADC case study illustrates how these strategies translate into precise targeting and potent cytotoxicity.

 

Multimodal biological assays — including cell-line cytotoxicity, high-content phenotyping, and molecular signalling markers such as Y-H2AX, RPA2, P53, PARP, and P21 — reveal ADC potency and mechanism-of-action, providing a physiologically relevant assessment of efficacy.

 

Complementing these efforts, specialised DMPK workflows for ADC discovery, including untargeted LC-HRMS profiling to characterise payload-related species, support understanding of ADC disposition and guide ADME and potential drug–drug interaction (DDI) study design, providing robust preclinical insights.

 

Join us to learn how integrated chemistry, biology, and DMPK strategies can streamline ADC discovery and support better early-stage decisions.

 

 You will learn about: 

• Strategies to optimise conjugation, linkers, and payloads across diverse ADCs

• Insights into ADC biological activity and mechanism-of-action

• Unique workflows for ADME characterisation of ADCs and payloads

• Practical insights and case studies from integrated ADC discovery, including Photo-ADC examples